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Abstract: 
Dapiprazole HCl ophthalmic eyedrops have been recently 
introduced to the optometric profession, and more specifically to 
optometrists practicing in therapeutic states. This diagonostic drug is 
used in reversing mydriasis induced by adrenergic or 
parasympatholytic agents. This is a literature review which covers 
the entire scope of dapiprazole HCl, or better known as Rev-Eyes, 
with special emphasis on the specific research studies and the 
subjective reported side effects, both systemic and ocular. 
Key Words; 
alpha-adrenergic blocker, dapiprazole, dapiprazole HCl, 
eyedrops, miotic, mydriatic, phenylephrine, Rev-Eyes, tropicamide. 
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Introduction: 
The use of dilation as part of the optometric examination began 
with the passage of the law allowing optometrists to use diagnostic 
drugs in Rhode Island in 1971. By 1989 every state in the nation 
had enacted a diagnostic drug law for optometrists. At first, 
ophthalmologists objected to this, but are now claiming that 
optometrists should adhere to the same standards as opthalmology 
when diagnosing ocular disease.! Although every institution and 
practitioner has varying ideas on when or how often to dilate a 
patient, most would tend to agree that dilation is a becoming the 
standard of care for optometrists.!· 12 With this being part of the 
routine ocular examination, there is the question of quick reversal of 
mydriasis to reduce the risk of accidents for patients who leave the 
office fully dilated, and to decrease patient complaints of glare and 
reduced near vision. 
There is a new diagnostic ocular pharmaceutical commonly 
known by its trade name, Rev-Eyes. It is a topical alpha-adrenergic 
antagonist called dapiprazole HCI. It has been shown to be more 
effective than another alpha-adrenergic antagonist, thymoxamine, 
and more safe than pilocarpine, a cholinergic antagonist, to reverse 
mydriasis .2.4,7 Extensive research has been done in both rabbit and 
human eyes to study any ocular or systemic side effects.2 -11 
To reverse mydriasis and cycloplegia is complicated in terms of 
safety and speed. Certain topical agents have been attempted before 
the introduction of dapiprazole HCl, including pilocarpine, which is 
commonly used in the treatment of glaucoma.2 Unfortunately, 
pilocarpine produces ocular pain caused by the spasm of 
accommodation in the ciliary muscle, blurred vision, and it . may 
induce pupillary block due to a shallowing of the anterior chamber 
and leading to possible angle closure glaucoma.2,3,8 Dapiprazole does 
not have any significant activity on the ciliary muscle contraction; 
therefore, it does not cause significant change in the anterior 
chamber depth or lens thickness. 8 The manufacturers claim that 
dapiprazole is safe and effective to reverse the effects of 
phenylephrine, an adrenergic agonist, and to a lesser degree, 
tropic amide, a cholinergic antagonist. 6, 8 It may partially increase 
accommodative amplitude which is decreased by tropicamide. 5. 7. 8 
2 
Instructions for use: 
0.5% dapiprazole hydrochloride is a sterile topical solution 
which is obtained in a form to be mixed by the eye care practitioner. 
A white, odorless powder is combined with a dilutent and dispensed 
via an anti-gravity dropper. The reconstituted solution is clear, 
colorless, and slightly viscous, and lasts twenty-one days at room 
temperature. It should be discarded after that time or sooner if the 
solution becomes discolored. 
Recommended use is to instill two drops in each eye, then five 
. minutes later instill two more drops8; however, published studies 
differ substantially in the dosage used, so a standard dose has not 
yet been established. Dapiprazole should not be used in the same 
patient more frequently than once per week. I 0 
Chemical Contents: 
Rev-Eyes is marketed by Storz Ophthalmics, Inc. as a kit 
consisting of one 25 mg vial of dapiprazole HCl, one 5 ml vial of 
dilutent and a dropper for dispensing. 8 
The contents include the inactive ingredients of mannitol, 2% 
sodium chloride, hydroxypropyl methylcellulose, 0.4% edetate 
sodium, 0.01% sodium phosphate dibasic, and sodium phosphate 
monobasic. The preservative used is 0.01% benzalkonium chloride. 
It is soluble in sterile saline. Dapiprazole HCl has the emperical 
formula C19H27N5HC1. It has a molecular weight of 361.93 and a 
melting point between 193.5 and 196.0 degrees Celsius.6 The 
chemical name is 3-[2-[4-(2-methylphenyl)-1-piperazinyl] ethyl]-
5 ,6, 7,8 ,-tetrahydro-1 ,2,4-triazole[ 4,3 -alpyuridine] HCI6 and has the 
following structural formula: 
• HCt 
3 
Mechanism of Action: 
Dapiprazole HCl is a sympatholytic whose miOtic abilities work 
by blocking the alpha-adrenergic receptors in the smooth dilator 
muscle of the iris. It does not alter the anterior chamber depth or 
cause the lens to thicken and move forward because the ciliary 
muscle is not effected by contractions.3,8 It has been found that a 
change in lOP does not occur with either a normal or increased 
pressure. Minimal systemic absorption has been noted in clinical and 
laboratory studies.6 Miosis can be seen within one hour of the last 
instillation and lasts up to six hours.3 ,5 
Cautions and Warnings By the Manufacturer: 
Use of dapiprazole is contraindicated in patients with acute 
1nt1s or hypersensitivity to the ingredients, especially the 
preservative, benzalkonium chloride (BAK). There is an increase in 
the number of liver tumors seen with long term high daily dosages 
when used in rats (the dose given was 80,000 times the normal 
human dose administered post-mydriasis). No side effects have been 
seen in pregnancy; however, no adequate and well controlled studies 
in pregnant women have been conducted. The manufacturer of 
dapiprazole, Abbott Laboratories, does advise caution if used in 
pregnant women. Caution should be exercised when administering 
this drug to nursing mothers, since many drugs are excreded in 
human milk; however, this drug has not been found in the secretions 
of human milk. The safety and efficacy of dapiprazole in children 
has not been established, and therefore should not be used in 
pediatric patients. In general, standard toxicologic tests "indicate 
that dapiprazole is without significant toxicity at dose levels which 
greatly exceed the human pharmacologic dose."8 
Adverse Reactions: 
Rev-Eyes, a noncholinergic agent, has no effect on pupillary 
block or blurred vision.3,8 There are no significant general systemic 
symptoms involving cardiovascular rate or blood pressure. 6 · 7 
Reported side effects include all of the following: bulbar conjunctival 
injection, browache, burning, chemosis, corneal edema, dry eye, 
fluorescein staining of the corneal epithelium, itching, lid edema, lid 
erythema, palpebral conjunctival injection, ptosis, and tearing.3 ,8 
Most of these are due to the dilation of the conjunctival blood 
vessels from alpha-adrenergic blocking action of dapiprazole. 6, 8 
4 
Clinical Studies: 
Results of studies performed by the companyB which 
manufactures dapiprazole HCl are promising to achieve safe and 
rapid reversal of mydriasis. With only phenylephrine as the dilating 
agent, dapiprazole returned 67% of mydriatic pupils to baseline 
values within thirty minutes and 88% of the pupils by one hour 
compared to only 7% of the control group. Accommodative 
amplitude baseline values were calculated at 7.6 diopters. After 
one-half hour after the last instillation of dapiprazole, treated pupils 
had 6.8 diopters of accommodation versus the control group which 
had only 5. 7 diopters. Treated groups returned to baseline after two 
hours, whereas the control group took longer than six hours. There is 
a lesser effect with the use of tropicamide, since it produces a greater 
degree of mydriasis and a greater decrease on accommodation. After 
two hours, 38% of the tropicamide treated subjects were reversed 
versus only 5% of the controls. They conclude by stating that by 
using dapiprazole HCl, you will make a significant contribution to 
your patients' convenience and well being. 
Nyman and Keates6 studied the side effects of dapiprazole on 
forty subjects. Of those, seven showed treatment emergent adverse 
reactions either during or after the study. Patient complaints 
included acne, dizziness, ear popping, fatigue, nausea, stiff neck and 
ankle, and upper respiratory infection with chest constriction. In 
these cases, the relation of these events with dapiprazole was remote 
and the case of acne is completely unproven to be a side effect. No 
significant difference was found in refraction, visual acuity, diastolic 
or systolic blood pressure, or pulse rate. Nyman and Keates 
concluded that treatment with dapiprazole is favored over no 
treatment when used to reverse the effects of 2.5% or 10% 
phenylephrine, 0.5% tropicamide, or a combination of 2.5% 
phenylephrine and 0.5% tropicamide. They theorized that the use of 
dapiprazole would reduce accidents caused by patients operating 
vehicles or machinery post-dilation, gives patient comfort and 
convenience, and would be useful in surgery where miosis is 
desirable. 
5 
In a study done by M.G. Bucci5, et al, performed on thirty 
subjects (60 eyes) using only 1% tropicamide as the mydriatic agent, 
it was found that constriction with Rev-Eyes begins 10 minutes after 
the last drop and about a 50% reversal occurs in most patients after 
one hour. The study consisted of ten healthy subjects, ten patients 
with chronic open angle glaucoma, and ten patients with chronic 
angle closure glaucoma. Three drops of 1% tropicamide were 
instilled with five minutes between drops. The baseline pupil mean 
value was 2.95 mm in both eyes. This evoked a pupil size no less 
than 6.50 mm in each eye. One eye was used as the control while the 
other eye received 0.5% dapiprazole HCI. After ten minutes, there 
was no change in miosis in the control eye and a 9.56% reduction in 
the treated eye. After three hours, the control pupil decreased to a 
mean value size of 6.60 mm while the treated pupil decreased to 
3.80 mm, a 44.1% reduction. As part of their study, the authors 
looked at lOP measurements post-mydriasis, ten minutes post-
miosis, and three hours post-miosis in those subjects with chronic 
angle closure glaucoma. Mean lOP for the control eye was 24.67 mm 
Hg and the mean value for the treated eye was 26.90 mm Hg. Ten 
minutes post-miosis, the control group read 28.00 mm Hg and in 
three hours was 27.22 mm Hg. In the treated group, the ten minute 
post-miosis was 29.40 mm Hg and after three hours read 25.40 mm 
Hg. They concluded that "dapiprazole HCl is a valid miotic agent that 
antagonizes the mydriasis that is induced by parasympatholytics" 
and reduces the .risk of dilation in chronic angle closure patients. 
In a more relevant study to optometry, Richard W. Allinson?, et 
al, demonstrated similar results to the M.G. Bucci study; however, 
Allison's study dealt with both the systemic and ocular effects using 
dapiprazole HCI. This was a clinical study using fifty subjects who 
were not on any medications which could affect pupillary reactions. 
They dilated patients using 1% tropicamide and 2.5% phenylephrine, 
the most commonly used dilating solutions for routine fundus 
examinations among optometrists and ophthalmologists. They found 
that there were no significant changes in heart rate, blood pressure, 
visual acuity, or lOP when using Rev-Eyes as a post-dilation miotic. 
6 
They measured a mean baseline pupil diameter in their subjects as 
3.70 mm. In the treated eyes, 52% went to baseline after two hours. 
Of the untreated eyes, none had returned to baseline after the two 
hour period. The main ocular symptom after using dapiprazole HCl 
was ocular injection and this was reported in 47 of the 50 subjects; 
however, it was categorized as mild and short term. They concluded 
that "dapiprazole may be an important addition to the topical agents 
available to the ophthalmologist" and the optometrist. 
An ultrasonic study on the ocular side effects of topical 
dapiprazole done by L. Bonomi3, et al, compared one drop of 2% 
pilocarpine with one drop of 0.5% dapiprazole. They found that 
dapiprazole produced miosis and decreased lOP just like its 
competitor, pilocarpine. However, few side effects were noted with 
dapiprazole. Pilocarpine induced accommodative spasm, thickening 
and forward displacement of the lens, narrowing of the anterior 
chamber depth, and had possibility of producing a pupillary block. 
Pilocarpine was more effective in giving a rapid decrease in pupil 
diameter: 36% decrease from mydriasis whereas dapiprazole 
revealed a 22% decrease. Patient symptoms with pilocarpine were 
reported as mild ocular pain and blurred vision. In a few cases, 
patients reported a transient burning sensation when dapiprazole 
w·as instilled. Since dapiprazole relaxes the radial iris muscle, it 
cannot induce a pupillary block. They concluded that "dapiprazole 
seems a promising candidate for use in those indications where 
miosis is needed, but cholinergic side effects are contraindicated. It 
may be considered for use in angle closure glaucomas." 
Laboratory Studies: 
L. B onomi 10 , et al, published an article in November, 1989 on 
the intraocular effects of dapiprazole in the rabbit eye. In their 
study, intraocular applications of 0.05% and 0.01% dapiprazole 
reversed mydriasis preoperatively induced by 10% phenylephrine 
and 0.5% tropicamide. No congestion of the ocular tissues occurred 
and no increase of the permeability of the blood-aqueous barrier 
resulted when compared to saline solution. No difference in corneal 
endothelium was observed in treated or untreated eyes. They 
concluded that dapiprazole would be useful in anterior segment 
surgery such as extracapsular cataract extraction (ECCE) and 
surgery for perforating injuries where miosis is beneficial. 
7 
A recent study at the Medical College of Georgia9 tested rabbit 
corneal endothelium for toxicity when intracamerally injected with 
dapiprazole hydrochloride. No toxicity was observed over three 
hours, until the concentration of dapiprazole exceeded 125 
micrograms/mi. At 250 micrograms/mi. an increased swelling rate 
of the corneal endothelium of 17.8 micrometers/ml was seen and 
showed a continuous and linear perfusion. The preservative, 
benzalkonium chloride (BAK) which enhances penetration of the drug 
through the cornea, induced the endothelial damage when not 
diluted to the manufacturers recommendations. Only 0.0001% BAK is 
needed to change the endothelium, whereas the 0.5% dapiprazole 
HCl ophthalmic solution contains 0.01% BAK. They suggested that 
topical use of this agent is safe; however its use as a post-surgical 
intracameral injecting agent should be inhibited. 
Conclusion: 
Dapiprazole appears to be a safe and efficacious topical 
ophthalmic drug to reverse the effects of mydriasis. It is not as 
successful in reducing the effects of tropicamide as it is with 
reducing the effects of phenylephrine. Systemic side effects are 
minimal. Ocular complaints are burning upon instillation in 
approximately 50% of the patients, minimal to severe conjunctival 
injection, and lid edema. The latter two symptoms can last up to 
three hours. 6 
Many patients will need to drive home, go back to work, or go 
out into the sunlight immediately after their exam. Practitioners 
must seriously consider the risk to these patients when allowing 
them to leave the eye care institution fully dilated. Some individuals 
are more sensitive to glare and headaches than others, and may 
postpone an eye exam to avoid the discomfort of a dilated fundus 
exam. An agent to reverse mydriasis would be advantageous in 
these and many other cases. 
We feel that the side effects might be reduced by decreasing 
the manufacturers recommended dosage from two drops to one drop 
per eye. A study of this nature would be beneficial. We would also 
recommend a study using proparacaine before the instillation of 
dapiprazole to reduce patient discomfort. Further research should 
be done to find a compatible preservative other than BAK, in attempt 
decrease the possible damage to the corneal endothelium. 
8 
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